Xgeva

ApprovedSmall molecule

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Xgeva is one of 37 small molecule programs targeting Giant Cell Tumor. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Giant Cell TumorActive, not recruiting

Prostate CancerActive, not recruiting

Giant Cell TumorApproved

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Xgeva

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Approved

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Ifex

BBaxter Healthcare Corporation

Preclinical

—9

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Post-ApprovalActive, not recruiting

Giant Cell Tumor

NCT04586660

Clinical

Trials by Indication[1]

Efficacy and Safety3 trials

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT04550949·700 enrolled

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Completed·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 3·NCT04812509·708 enrolled

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Unknown status· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 3·NCT04859569·850 enrolled

Immunogenicity3 trials

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Unknown status· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT04494373·154 enrolled

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults

Completed·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 1·NCT04798326·120 enrolled

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Unknown status· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT05777109·180 enrolled

Adult1 trial

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Completed· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT03651947·168 enrolled

Giant Cell Tumor1 trial

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Active, not recruiting· Amgen logo

Amgen·Phase 4·NCT04586660·36 enrolled

Prostate Cancer1 trial

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

Terminated·CCancer Trials Ireland·Phase 2·NCT03869762·7 enrolled

1 more indication

Unspecified1 trial

Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers

Withdrawn·TTaizhou Mabtech Pharmaceutical Co.,Ltd·Phase 1·NCT05808673

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Xgeva. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xgeva compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xgeva. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Hansoh Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Xgeva

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Efficacy and Safety3 trials

Immunogenicity3 trials

Adult1 trial

Giant Cell Tumor1 trial

Prostate Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News